Quinazolin‐4(3H)‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications
 
Yazarlar (5)
Doç. Dr. Feyzi Sinan TOKALI Kafkas Üniversitesi, Türkiye
Prof. Dr. Yeliz Demir Ardahan Üniversitesi, Türkiye
Arş. Gör. Şeyma Ateşoğlu Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Pelin Tokalı
Kafkas Üniversitesi, Veteriner Fakültesi, Türkiye
Doç. Dr. Halil Şenol Bezm-İ Âlem Vakıf Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Archiv Der Pharmazie (Q2)
Dergi ISSN 0365-6233 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 06-2025
Cilt / Sayı / Sayfa 358 / 6 / – DOI 10.1002/ardp.70033
Makale Linki https://doi.org/10.1002/ardp.70033
UAK Araştırma Alanları
Organik Kimya
Özet
A series of novel glitazones containing thiazolidine‐2,4‐dione and quinazolin‐4(3H)‐one moieties were synthesized to explore their potential as dual inhibitors of aldose reductase (ALR2) and α‐glucosidase (α‐Glu), two key enzymes involved in diabetes and its complications. In vitro assays revealed that compounds 8 (cyclohexyl substituted), 9 (phenethyl substituted), and 11 (phenyl substituted) exhibited potent inhibitory effects on both enzymes, with 11 being the most active, showing an ALR2 inhibition (Ki = 0.106 µM) approximately nine times more effective than the standard epalrestat (EPR) (Ki = 0.967 µM) and α‐Glu inhibition (Ki = 0.648 µM) about six times stronger than acarbose (ACR) (Ki = 0.3.775 µM). Molecular docking and molecular dynamics simulations showed that compound 11 formed strong interactions with residues Trp‐20, Gln‐183, and Asp‐43 for ALR2 and residues Arg‐200, Arg …
Anahtar Kelimeler
aldose reductase | diabetes | glitazones | quinazolin-4(3H)-one | thiazolidin-2,4-dione | α-glucosidase